next generation glp 1 drugs The Of Weight Loss Medications | Henry Ford Health GLP-1 2.0: Where the Next

Description

Recognizing obesity as a chronic disorder underscores the need for long-term pharmacological treatment, similar to the approach used for managing type 2 diabetes or hypertension to achieve optimal control

Recently, the results of a landmark randomized controlled trial showed treatment with tirzepatide (15 mg subcutaneous/week), a dual GLP-1R/GIP receptor (GIPR) agonist, caused an 18% placebo-subtracted weight loss (21% total weight loss) at 72 weeks in people with obesity (6)

Protective effects and mechanisms of polyethylene glycol loxenatide against hyperglycemia and liver injury in db/db diabetic mice

While these findings have not been conclusively observed in humans, the FDA has issued warnings about the potential risk

Results: While there is a wealth of pre-clinical animal data suggesting that GLP-1RAs can ameliorate experimental colitis, there is a lack of prospective clinical studies on treating active IBD with GLP-1RAs to specifically induce steroid-free clinical remission